Releases - PledPharma AB

View:
 

Found press releases

 

Rights issue in PledPharma oversubscribed

5/24/2013 8:00 AM EST
PledPharma AB
Company Announcement

Rights issue in PledPharma oversubscribed

Stockholm, 2013-05-24 14:00 CEST (GLOBE NEWSWIRE) --
PledPharmas rights issue with subscription period from 6 May to 20 May 2013 was
oversubscribed by 38 percent. PledPharma receives approximately SEK 18.6
million before issue costs.

The rights issue was subscribed to approximately 95 percent with preferential
rights and the...

PledPharma appoints advisor for the commercialization of PledOx®

5/6/2013 2:30 AM EST
PledPharma AB
Company Announcement

PledPharma appoints advisor for the commercialization of PledOx®

PledPharma intends to out-licence oncology compound PledOx starting in 2013 for
further development and commercialization. PledPharma has contracted with IMS
Consulting Group (IMSCG) as a strategic advisor to facilitate the process.

Stockholm, 2013-05-06 08:30 CEST (GLOBE NEWSWIRE) -- PledPharma is looking...

Interim Report First Quarter 2013

4/18/2013 8:00 AM EST
PledPharma AB
Interim information

Interim Report First Quarter 2013

First patient treated in the PledOx™ phase IIb study, PLIANT

Stockholm, 2013-04-18 14:00 CEST (GLOBE NEWSWIRE) --

Significant events after the end of the period

• PledPharma proposes a rights issue of shares that can provide the company
with up to 18.6 million SEK. The proposal will be tabled at an EGM to be held
in conjunction with the...

PledPharma today announces that the MANAMI study is fully recruited

4/18/2013 7:29 AM EST
PledPharma AB
Company Announcement

PledPharma today announces that the MANAMI study is fully recruited

All patients were included in the current small investigator initiated clinical
phase IIa trial MANAMI, which examines a PLED substance in patients with acute
myocardial infarction undergoing percutaneous coronary intervention (PCI).

Stockholm, 2013-04-18 13:29 CEST (GLOBE NEWSWIRE) -- In the ongoing...

PledPharma AB (publ) issues new shares

4/3/2013 12:58 PM EST
PledPharma AB
Company Announcement

PledPharma AB (publ) issues new shares

Specialty pharma company PledPharma proposes a rights issue of shares that can
provide the company with up to 18.6 million SEK. The proposal will be tabled at
an EGM to be held in conjunction with the AGM on April 18. The share issue is
done to achieve greater flexibility and time to perform the best possible
out-licensing deal of...

Go-ahead for PledPharma to proceed with PLIANT study patient recruitment

2/26/2013 3:42 AM EST
PledPharma AB
Company Announcement

Go-ahead for PledPharma to proceed with PLIANT study patient recruitment

PledPharma has received green light from the DSMB (Drug Safety Monitoring
Board), an independent panel of experts) to continue patient recruitment for
the phase IIb study PLIANT. The study will evaluate whether pretreatment with
PledPharma's drug candidate PledOx™ reduces the severe side effects caused...

PledPharma AB (publ) Full Year Report 2012

2/21/2013 2:30 AM EST
PledPharma AB
Interim information

PledPharma AB (publ) Full Year Report 2012

First patient treated in the PledOx™ phase IIb study, PLIANT

Stockholm, 2013-02-21 08:30 CET (GLOBE NEWSWIRE) --

Significant events after the end of the period

-- First patient treated at Uppsala University Hopsital (UAS) in the PledOx™
phase IIb study PLIANT
-- Patent application regarding the use of PLED compounds in...

PledPharma's patent application approved and issued in USA

2/20/2013 4:19 AM EST
PledPharma AB
Company Announcement

PledPharma's patent application approved and issued in USA

Stockholm, 2013-02-20 10:19 CET (GLOBE NEWSWIRE) -- PledPharma today announces
that it has received patent approval for the US market. This is the first
patent in a series of worldwide applications aiming to achieve exclusive and
broad commercial rights for manufacturing and use of PLED compounds, including
among...

First patient included into PledPharma’s PLIANT study

2/12/2013 3:02 PM EST
PledPharma AB
Company Announcement

First patient included into PledPharma’s PLIANT study

PledPharma announces today that the first patient has been enrolled in the
phase IIb study, PLIANT. This study will evaluate PledPharma's drug candidate
PledOx™ ability to reduce side effects caused by the chemotherapy FOLFOX in
patients treated for metastatic colorectal cancer.

Stockholm, 2013-02-12 21:02 CET (GLOBE...

PLIANT study starts in the U.S.

1/30/2013 4:55 AM EST
PledPharma AB
Company Announcement

PLIANT study starts in the U.S.

PledPharma expands recruitment to the dose-escalation phase of PLIANT study
with center in the U.S.

Stockholm, 2013-01-30 10:55 CET (GLOBE NEWSWIRE) -- To increase recruitment,
the study will also include the Cancer Therapy & Research Center at The
University of Texas Health Science Center at San Antonio., U.S. for the first
part of the...

PledPharma AB

RSS